Halladay Benjamin sold $34K of ESPR
Halladay Benjamin (Chief Financial Officer) sold 10,773 shares of Esperion Therapeutics, Inc. (ESPR) at $3.16 on 2026-06-17.
How this was made
The 30-second read
Why it matters
The newest fact is the CFO’s open-market sale details (shares, price, total value, post-transaction holdings). No new business, clinical, or regulatory information is included.
Market read
Traders may monitor insider activity as a sentiment input, but this specific disclosure lacks fundamental catalysts.
What to watch
Check for follow-on insider transactions (buys/sells by other officers/directors) and whether the sale coincides with upcoming catalysts (earnings, trial readouts) not mentioned here.
Background
The article is an SEC Form 4 insider transaction disclosure for Esperion Therapeutics, Inc.
Ticker impact
Esperion Therapeutics CFO Halladay Benjamin sold 10,773 shares at $3.1550 on 2026-06-17 via an open-market sale.
Likely limited near-term impact; treat as low-signal unless repeated or paired with other negative disclosures.
The filing is a primary-source insider transaction, but it is not tied to new company fundamentals, and the size/value is modest relative to typical market-moving events.
Market effects
No sector read-across; this is company-specific insider activity without additional regulatory/clinical context.
None indicated.
None indicated.
Counterpoint
Insider sales can be planned for liquidity/tax needs; the absence of a 10b5-1 plan doesn’t automatically imply negative expectations.
Key entities
- issuerEsperion Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderHalladay Benjamin
Chief Financial Officer who reported the sale.